Benign prostatic hyperplasia in primary care: What you need to know

Journal of Urology

Volumn 175, Issue 3 SUPPL., 2006, Pages

  Burnett, Arthur L ^a,c   Wein, Alan J ^b  

^a Hopkins University   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NONE   (United States)

Author keywords

Benign prostatic hyperplasia; Bladder neck obstruction; Prostate; Urination disorders

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE; TAMSULOSIN; TERAZOSIN; TOLTERODINE;

ALTERNATIVE MEDICINE; ANGINA PECTORIS; DRUG MECHANISM; DYSPNEA; EDEMA; FATIGUE; GYNECOMASTIA; HEADACHE; HEART ARRHYTHMIA; HISTOLOGY; HUMAN; IMPOTENCE; INCIDENCE; LIBIDO DISORDER; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; RHINITIS; SEXUAL DYSFUNCTION; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; URINE RETENTION;

EID: 31744442454     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00310-1     Document Type: Article

References (27)

1. C.G. Roehrborn, J.D. McConnell Etiology, pathophysiology, epidemiology and natural history of BPH P.C. Walsh A.B. Retik E.D. Vaughan Jr A.J. Wein Campbell's Urology 2002 W. B. Saunders Co Philadelphia
2. J. Nordling, W. Artibani, T. Hald, T. Horn, F. Keuppens, R. Levin Pathophysiology of the urinary bladder in obstruction and aging C. Chatelain L. Denis K.T. Foo S. Khoury J. McConnell Benign Prostatic Hyperplasia 2001 Health Publication Ltd Plymouth, United Kingdom
3. C.G. Roehrborn 5-α-Reductase inhibitors prevent the progression of benign prostatic hyperplasia Rev Urol 5 suppl. 2003 S12
4. J.D. McConnell, M.J. Barry, R.C. Bruskewitz Agency for Health Care Policy and Research Publication No. 94-0582 Benign Prostatic Hyperplasia Diagnosis and Treatment 1994 Agency for Health Care Policy and Research Rockville, Maryland
5. J.V. Jepsen, R.C. Bruskewitz Office evaluation of men with lower urinary tract symptoms Urol Clin North Am 25 1998 545
6. P.H. Abrams, D.J. Farrar, R.T. Turner-Warwick, C.G. Whiteside, R.C. Feneley The results of prostatectomy a symptomatic and urodynamic analysis of 152 patients J Urol 121 1979 640
7. D.A. Schwinn Novel role for a1-adrenergic receptor subtypes in lower urinary tract symptoms BJU Int 86 suppl. 2000 11
8. C. Chatelain, L. Denis, K.T. Foo, S. Khoury, J. McConnell Recommendations of the International Scientific Committee Benign Prostatic Hyperplasia 2001 Health Publication Ltd Plymouth, United Kingdom
9. Leveillee, R. J., Patel, V. and Bird, V. G.: Prostate hyperplasia, benign. Available at http://www.emedicine.com/med/topic1919.htm. Accessed February 17, 2005.
10. AUA, Practice Guideline Committee AUA guidelines on management of benign prostatic hyperplasia: (2003). Chapter 1: diagnosis and treatment recommendations J Urol 170 2003 530
11. J. McLoughlin, K.P. Gill, P.D. Abel, G. Williams Symptoms versus flow rates versus urodynamics in the selection of patients for prostatectomy Br J Urol 66 1991 303
12. C.G. Roehrborn Focus on lower urinary tract symptoms nomenclature, diagnosis, and treatment options Rev Urol 3 2001 139
13. J.J. De La Rosette, B.B. Kortmann, C. Rossi, G.S. Sonke, D.L. Floratos, L.A. Kiemeney Lomg-term risk of re-treatment of patients using alpha blockers for low urinary tract symptoms J Urol 167 2002 1734
14. Cardura® package insert 2002 Pfizer New York
15. Flomax® package insert 2004 Boehringer Ingelheim Pharmaceuticals Ridgefield, Connecticut
16. Hytrin® package insert 2001 Abbott Laboratories North Chicago
17. UroXatral® package insert 2003 Sanofi-Synthelabo New York
18. Avodart™ package insert 2004 GlaxoSmithKline Research Triangle Park
19. Proscar® package insert 2004 Merck and Co Whitehouse Station, New Jersey
20. G. Bartsch, J.D. McConnell, C. Mahler, F. Calais Da Silva, H. Klocker, F. Richard Endocrine treatment of benign prostatic hyperplasia C. Chatelain L. Denis K.T. Foo S. Khoury J. McConnell Benign Prostatic Hyperplasia 2001 Health Publication Ltd Plymouth, United Kingdom
21. J.D. McConnell, C.G. Roehrborn, O.M. Bautista, G.L. Andriole Jr., C.M. Dixon, J.W. Kusek The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387
22. R.A. Appell Overactive bladder in special patient populations Rev Urol 5 suppl. 2003 S37
23. P. Abrams, S.H. Kaplan, R. Millard Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO) Neurourol Urodyn 20 2001 547
24. A. Athanasopoulos, K. Gyftopoulos, K. Giannitsas, J. Fisfis, P. Perimenis, G. Barbalias Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction a prospective, randomized, controlled study J Urol 169 2003 2253
25. G.S. Gerber, D. Kuznetsov, B.C. Johnson, J.D. Burstein Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms Urology 58 2001 960
26. A.E. Gordon, A.F. Shaughnessy Saw palmetto for prostate disorders Am Fam Physician 67 2003 1281
27. R.C. Flanigan, D.J. Reda, J.H. Wasson, R.J. Anderson, M. Abdellatif, R.C. Bruskesitz 5-Year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign hyperplasia a Department of Veterans Affairs cooperative study J Urol 160 1998 12